Business Context and Reporting Period
This Form 8-K filing by Bionano Genomics, Inc. (BNGO) reports a corporate governance event dated December 21, 2021. The company is an emerging growth company incorporated in Delaware with principal executive offices in San Diego, California.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on the appointment of a new director and associated compensation arrangements.
Material Changes
The material change reported is the appointment of Vincent J. Wong as a Class I director, effective December 21, 2021. His term will serve until the Company's 2022 annual meeting of stockholders.
Management Commentary and Compensation Details
- Director Compensation: Mr. Wong will receive annual cash compensation of $40,000, payable in equal quarterly installments and pro-rated based on days served.
- Equity Grant: On December 21, 2021, Mr. Wong was granted a stock option to purchase 122,054 shares of common stock under the 2018 Equity Incentive Plan.
- Vesting Schedule: The option vests in equal monthly installments over a three-year period, contingent on continuous service. Full vesting occurs upon a Change in Control.
- Indemnification: The Company entered into a standard indemnification agreement with Mr. Wong.
Investor Verification Checklist
- Verify the total number of outstanding shares and the impact of the 122,054 new options on potential dilution.
- Review the Company's 2018 Equity Incentive Plan to confirm the exercise price of the granted options.
- Confirm the total number of directors on the Board following this appointment.
- Check subsequent filings for any changes to the Non-Employee Director Compensation Policy.